Substantial pharmaceutical research has been done on fucoidan, focusing primarily on two distinct forms: F-fucoidan, which is >95% composed of sulfated esters of fucose, and U-fucoidan, which is approximately 20% glucuronic acid. As a consequence of this research, U-fucoidan and F-fucoidan are now being marketed as a nutraceutical and food supplement.[1][2]
A study [3] released in 2005 by Japanese researchers have indicated that F-fucoidan can induce apoptosis in human lymphomacell lines; as well, French researchers showed in 2002 [4] that F-fucoidan can inhibit hyperplasia in rabbits.
A study at the Statens Serum Institute, in Copenhagen, showed that, after pre-treatment with Fucoidan, deaths of rats infected with meningitis increased. 21 out of 45 rats that had been given Fucoidan and then treated after infection with an antibiotic died; as compared with 5 deaths out of 29 for those had not been given Fucoidan and had been treated with only the antibiotic.[5]
^ Elkins, Rita, Limu Moui, prize Sea Plant of the South Pacific, Woodland Publishing, 2001
^ Aisa Y; Miyakawa Y; Nakazato T; Shibata H; Saito K; Ikeda Y; Kizaki M (2005 Jan). "Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways". American Journal of Hematology78 (1): 7–14. doi:10.1002/ajh.20182. PMID 15609279doi:10.1002/ajh.20182.
^ Pretreatment with Fucoidan Promotes Lethal Infection in a Rat Model of Experimental Pneumococcal Meningitis. Brandt C, Lundgren Jd, Lund Sp, Frimodt-Moller N, Christensen T, Benfield T, Espersen F, Hougaard D, Ostergaard C; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).